Delivery Order 75N93022D00007-75N93024F00001

Sri International has been awarded a delivery order valued at $2.15M under the Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS) master indefinite-delivery/indefinite-quantity contract with the National Institute of Allergy and Infectious Diseases (NIAID). The award, issued on August 1, 2024, with an ultimate completion date of August 1, 2029, funds a Good Laboratory Practice (GLP) toxicology study for adjuvanted HIV-1 immunogen vaccine candidates. The contract is structured as cost-plus-fixed-fee and carries no small business set-aside designation. Work will be performed at Sri International's Menlo Park, California facility.

To support the toxicology study, Sri International has engaged Charles River Laboratories, Inc. as a major subcontractor for laboratory animal procurement and services, with that subcontract awarded on October 1, 2025. Charles River is a leading contract research organization specializing in providing laboratory animals and preclinical research services critical to vaccine development and safety evaluation efforts. This subcontract arrangement aligns with NIAID's mission to support advanced vaccine development through comprehensive preclinical safety and efficacy assessment, leveraging both Sri International's research and development capabilities and Charles River's specialized expertise in animal model provision and toxicology support services.